Apel­lis’ C3 in­hibitor shows bio­mark­er im­pact in small PhII rare kid­ney dis­ease tri­al

Apel­lis Phar­ma­ceu­ti­cal’s pegc­eta­coplan has shown hints of ef­fi­ca­cy in a hand­ful of pa­tients with rare kid­ney dis­eases in a Phase II tri­al, five months af­ter …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER